Intake of Commercially Produced Fermented Soy Powder Q CAN PLUS® Favorably Changes Cholesterol and Isoflavone Intake in Individuals at High Risk of Cardiovascular Disease
Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile...
Saved in:
Published in | Current developments in nutrition Vol. 4; no. Supplement_2; p. nzaa045_041 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Inc
01.06.2020
Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 2475-2991 2475-2991 |
DOI | 10.1093/cdn/nzaa045_041 |
Cover
Abstract | Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase.
Study design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7.
On average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase.
The differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases.
BESO Biological Research Inc Diamond Bar, CA, USA. |
---|---|
AbstractList | ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase.MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7.ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase.ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases.Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA. Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase. Study design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7. On average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase. The differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases. BESO Biological Research Inc Diamond Bar, CA, USA. ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase.MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7.ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower (P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher (P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase.ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases.Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA. AbstractObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the nutrient composition of the habitual diets of individuals at high risk of cardiovascular diseases. We hypothesized that the nutrient profile, particularly nutrients associated with CVD risk, differs among individuals in the Q CAN PLUS® phase compared to the placebo phase. MethodsStudy design was a randomized, controlled crossover intervention with twenty-four free living adults (29–75 years old; 80% female; 8% normal BMI, 45% overweight, 47% obese) at high risk of cardiovascular diseases. Subjects were randomized to receive either Q CAN PLUS® (fermented soy) powder or placebo powder for twelve weeks and switched over to the placebo treatment after two weeks of wash out period. Two 24-hour dietary recalls were collected during each phase which included one weekday and one weekend dietary recall. The nutrient consumption per day (mean ± SD) were based on a synthetic week by using the following formula: ((weekday * 5) +(weekday * 2))/7. ResultsOn average, intake of cholesterol (211 ± 169 mg) was 13% lower ( P = 0.05) in the Q CAN PLUS® phase compared to placebo (243 ± 179 mg). Total soy isoflavones (444 ± 210 mg) was 12 times higher ( P < 0.0001) during Q CAN PLUS® phase than the placebo phase (33 ± 93 mg). Dietary total carbohydrate, total protein, vegetable protein, animal protein during Q CAN PLUS® phase were not statistically different from placebo phase. ConclusionsThe differences in the intake of cholesterol and total soy isoflavones may have implications on risk of cardiovascular diseases. Funding SourcesBESO Biological Research Inc Diamond Bar, CA, USA. |
ArticleNumber | nzaa045_041 |
Author | Haddad, Ella Jung, Sarah Sabaté, Joan Kim, Alice Sirirat, Rawiwan |
AuthorAffiliation | 1 Loma Linda University, School of Public Health 3 Loma Linda University 2 Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health |
AuthorAffiliation_xml | – name: 2 Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health – name: 3 Loma Linda University – name: 1 Loma Linda University, School of Public Health |
Author_xml | – sequence: 1 givenname: Sarah surname: Jung fullname: Jung, Sarah organization: Loma Linda University, School of Public Health – sequence: 2 givenname: Rawiwan surname: Sirirat fullname: Sirirat, Rawiwan organization: Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health – sequence: 3 givenname: Alice surname: Kim fullname: Kim, Alice organization: Loma Linda University, School of Public Health – sequence: 4 givenname: Ella surname: Haddad fullname: Haddad, Ella organization: Loma Linda University – sequence: 5 givenname: Joan surname: Sabaté fullname: Sabaté, Joan organization: Center for Nutrition and Healthy Lifestyles, Loma Linda University School of Public Health |
BookMark | eNqNUl1v0zAUjdCQGGPPvFriDanUduIkfpk0BcoqVTAok3izHPum9ZrYxU6Cyl9C4kfwy3BpNQ0kJp7ulX3OuR_nPk1OrLOQJM8JfkUwT6dK26n9JiXOmMAZeZSc0qxgE8o5ObmXP0nOQ7jFGBPOeY75afJ9bnu5AeQaVLmuA6-MbNsduvZODwo0moHvwPYxW7r47L5q8OgDqi7foevFzfLnDzSTo_OyjqRqLe0KQoyuhdCDdy2SVqN5cE0bURbQsZyxMdNmNHqQbUCyR1dmtUYfTdj8bkV6bdwogxpa6dFrE0AGeJY8biIazo_xLLmZvflUXU0W79_Oq8vFRKWMkklRFJBlADUjtC44xjqlpWRNzihVJWa4KRlQ1TQ5ZXXKi5TxBuuG1JgTmdU8PUsuDrrboe5Aqzi-l63YetNJvxNOGvHnjzVrsXKjKCgrCcVR4MVRwLsvQ9yEuHWDt7FnkZKcs4KXmEbU9IBS3oXgobmrQLDYuyqiq-Keq5Hx8sBww_Y_wPwAhriq0YAXQRmw0VPjQfVCO_MA9-IvrmqNNUq2G9hBuJuGiEAFFsv9ge3vi6a44DT_HAWKfws8WPoXcU7lfw |
ContentType | Journal Article |
Copyright | 2020 American Society for Nutrition. American Society for Nutrition. Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. 2020 Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. |
Copyright_xml | – notice: 2020 American Society for Nutrition. – notice: American Society for Nutrition. – notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. 2020 – notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2020. |
DBID | 6I. AAFTH AAYXX CITATION 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.1093/cdn/nzaa045_041 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
DocumentTitleAlternate | NUTRITION 2020 LIVE ONLINE Abstracts |
EISSN | 2475-2991 |
EndPage | nzaa045_041 |
ExternalDocumentID | PMC7258120 10_1093_cdn_nzaa045_041 10.1093/cdn/nzaa045_041 S247529912307926X 1_s2_0_S247529912307926X |
GeographicLocations | United States--US |
GeographicLocations_xml | – name: United States--US |
GroupedDBID | .1- .FO 0R~ 7RV 7X7 8FI 8FJ AAFWJ AAHBH AALRI AAPXW AAVAP AAXUO AAYWO ABPTD ABUWG ABXVV ACGFS ACVFH ADBBV ADCNI ADVLN AEUPX AFJKZ AFKRA AFPKN AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMNDL AMRAJ AOIJS APXCP BAYMD BCNDV BENPR CCPQU EBS EJD EMOBN FDB FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR INH ITC KSI M~E NAPCQ O9- OK1 PHGZM PHGZT PIMPY PPXIY PUEGO RPM UKHRP Z5R 6I. AAFTH ABDBF ABEJV AFULF BTTYL ROX TOX AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c3521-777e44eeb512b7900d328a5f6522c8050f85e2cff625b397359f0df1b091a4b93 |
IEDL.DBID | 7X7 |
ISSN | 2475-2991 |
IngestDate | Thu Aug 21 13:56:58 EDT 2025 Fri Jul 25 09:20:55 EDT 2025 Wed Aug 06 19:27:10 EDT 2025 Tue Nov 19 12:02:23 EST 2024 Sat Aug 30 17:16:51 EDT 2025 Fri Aug 08 06:00:38 EDT 2025 Tue Aug 26 16:33:04 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_2 |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3521-777e44eeb512b7900d328a5f6522c8050f85e2cff625b397359f0df1b091a4b93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
OpenAccessLink | https://www.proquest.com/docview/3169579802?pq-origsite=%requestingapplication% |
PQID | 3169579802 |
PQPubID | 7121353 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7258120 proquest_journals_3169579802 crossref_primary_10_1093_cdn_nzaa045_041 oup_primary_10_1093_cdn_nzaa045_041 elsevier_sciencedirect_doi_10_1093_cdn_nzaa045_041 elsevier_clinicalkeyesjournals_1_s2_0_S247529912307926X elsevier_clinicalkey_doi_10_1093_cdn_nzaa045_041 |
PublicationCentury | 2000 |
PublicationDate | 20200601 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 20200601 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford |
PublicationTitle | Current developments in nutrition |
PublicationYear | 2020 |
Publisher | Elsevier Inc Oxford University Press |
Publisher_xml | – name: Elsevier Inc – name: Oxford University Press |
SSID | ssj0001999609 |
Score | 2.1078498 |
Snippet | Q CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN PLUS® on the... AbstractObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of... ObjectivesQ CAN PLUS® is a fermented soy powder currently marketed in the US as a food product. We conducted a feeding trial to examine the effects of Q CAN... |
SourceID | pubmedcentral proquest crossref oup elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | nzaa045_041 |
SubjectTerms | Cardiovascular disease Cholesterol Dietary Bioactive Components Gastroenterology and Hepatology Proteins |
Title | Intake of Commercially Produced Fermented Soy Powder Q CAN PLUS® Favorably Changes Cholesterol and Isoflavone Intake in Individuals at High Risk of Cardiovascular Disease |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S247529912307926X https://www.clinicalkey.es/playcontent/1-s2.0-S247529912307926X https://dx.doi.org/10.1093/cdn/nzaa045_041 https://www.proquest.com/docview/3169579802 https://pubmed.ncbi.nlm.nih.gov/PMC7258120 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3dbtMwFLZgu-EGAQNRGJUlEOImquM4P75CZazaEFRlpVLvLDu2RbXijKWAxish8RA8GcdO0i0SG1eJkhzb0Tn2-Xz-jNALnjGTWaminEkSsaQkES8pj0yhJLNFBhrZ2zs-TLOjBXu3TJetwa1uwyq7NTEs1LoqvY18lMSZ9ygVhL4--xr5U6O8d7U9QuM22g2ly0Ce82V-aWPxaJ7wrqIPT0aldiP3U0oAMoKw-Dpl1Mt185CzHzB5RQNN7qG7LXTE44bX99Et4x6gvbGDbfOXC_wSh2DOYCXfQ7-O3UaeGlxZ7FNA_LFKcr2-wLNQ4NVoPIEV2Zfj1HhewePqhzbn-CM-GE_x7P1i_uc3nsjvIB4KiJoMhBquvvoTMKJaY-k0Pq4ru4avnMFtdysHd12GV43lBvs4Enyyqk_DUHrBr_ht4xx6iBaTw08HR1F7LkNUAlyLAZDnhjFjFIAFlXNCdEILmdoMsFxZkJTYIjW0tBb2VgrwTpJyS7SNFWATyRRPHqEdB2N7jLAhNtM2V5xoCcCNc0VJIkuTUmMtY2SAXnUMEmdN-Q3RuM0TAbwUV3g5QKRjoOiySmEdFKAarifJ_0Vi6nYe1yIWNRVEzCnLU1DcsQ-b5zRbDhDdUrZQpYEgN3f3HOTq__-x38md2I7jUvphzD1Z3Dbn64T337jV51AvPKcpwDjy5OaGn6I71NsSgoVpH-1szr-ZZwC4NmoYZtUQ7b45nM5OhsFs8RemnDLK |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V7QEuCCiIQIGReIiLlfV6_TogFNpGCU2j0DRSbsuuvSuiBrvUgSr8JaT-CH4Zs36kjUTLqSdbtvdhzezMN7Mzs4S8jgOuAyOVE3JJHe4l1IkTFjs6UpKbKECNbP0dh8OgN-Gfpv50g1w0uTA2rLKRiaWgTvPE-sjbnhvYHaWIsg-n3x17apTdXW2O0KjY4kAvz9FkK97395C-bxjr7h_v9pz6VAEnQbDhIpwMNedaK1R1KowpTT0WSd8EiESSiPrURL5miTFoGSjU1p4fG5oaV6FmlVzZ4kso8re4zWjdJFsf94ejo0uvjrUfaNzUEIq9dpJm7eyXlAidBOXudepvLbvOgtz1EM0rOq97n9yrwSp0Ku56QDZ09pBsdzI01L8t4S2U4aOlX36b_O5nC3miITdgk07sQU5yPl_CqCwpq1Poog6wBUBTGOf4OD9P9Rl8ht3OEEaDyfjPBXTlT2RIhY2qnIcCr7beFJI-n4PMUugXuZnjV5mGerhZhndNTlkBcgE2cgWOZsVJOZW1cFvYq7ajHpHJrdDsMdnMcG5PCGhqgtSEKqaptDSMFaOeTLTPtDGc0xZ51xBInFYFP0S1Ue8JpKW4QssWoQ0BRZPHipJXoDK6vkn4rya6qCVHIVxRMEHFmPHQR6jg2kD9mAXTFmGrljU4qkDPzcO9Qr76_3_sNHwnVvO4XG845zVeXHVnK5Ovv8lmX8sK5SHzETjSpzd3_JLc6R0fDsSgPzx4Ru4y68ko_Vs7ZHNx9kM_R7i3UC_qNQbky20v67_dcmy2 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intake+of+Commercially+Produced+Fermented+Soy+Powder+Q+CAN+PLUS%C2%AE+Favorably+Changes+Cholesterol+and+Isoflavone+Intake+in+Individuals+at+High+Risk+of+Cardiovascular+Disease&rft.jtitle=Current+developments+in+nutrition&rft.au=Jung%2C+Sarah&rft.au=Sirirat%2C+Rawiwan&rft.au=Kim%2C+Alice&rft.au=Haddad%2C+Ella&rft.date=2020-06-01&rft.pub=Oxford+University+Press&rft.eissn=2475-2991&rft.volume=4&rft.issue=Suppl+2&rft.spage=408&rft.epage=408&rft_id=info:doi/10.1093%2Fcdn%2Fnzaa045_041&rft.externalDocID=PMC7258120 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F24752991%2FS2475299120X04148%2Fcov150h.gif |